|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||88.74 - 89.54|
|52 Week Range||67.65 - 95.06|
|Beta (5Y Monthly)||0.49|
|PE Ratio (TTM)||33.42|
|Earnings Date||Jul 29, 2020|
|Forward Dividend & Yield||3.15 (3.53%)|
|Ex-Dividend Date||May 04, 2020|
|1y Target Est||82.62|
Shares of Regeneron Pharmaceuticals Inc. were up 2.1% in trading on Thursday as SunTrust Robinson Humphrey analysts upgraded the stock to buy from hold, citing the strength of the company's drug pipeline. In a July 8 note to investors, they said that Regeneron's base business, which includes macular degeneration drug Eylea and atopic dermatitis therapy Dupixent, has remained strong during the COVID-19 pandemic. SunTrust analysts also said that the company's work on experimental COVID-19 therapies is an indicator of its "innovation engine." The company is currently testing an experimental antibody cocktail candidate as a treatment for COVID-19 as well as to see if the therapy can prevent infection; however, Regeneron also said last week that a trial examining whether rheumatoid arthritis drug Kevzara, which Regeneron co-developed with Sanofi , could work as a COVID-19 drug had failed in a late-stage study. Regeneron's stock has gained 72.9% year-to-date. The S&P 500 is down 1.8% for the year.
A new $1 billion fund backed by 20 drugmakers including Merck & Co Inc and Pfizer Inc is aiming to bolster struggling antibiotic companies and sustain a pipeline for new treatments, an industry group said on Thursday. Public health authorities have raised alarms about a looming health crisis, saying deaths from antibiotic-resistant bacteria could dwarf that from the coronavirus pandemic. The new fund, led by the International Federation of Pharmaceutical Manufacturers & Associations, has raised nearly $1 billion so far and aims to help shore up investment in smaller biotech companies after several large drugmakers, such as Sanofi SA bowed out of the space.
Kymera Therapeutics Inc. today announced the company has entered into a multi-program strategic collaboration with Sanofi (NASDAQ: SNY) to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases. The companies will also partner on a second earlier stage program. Kymera will receive $150 million in cash upfront and may receive more than $2 billion in potential development, regulatory and sales milestones, as well as significant royalty payments. Kymera retains the option to participate in US development and commercialization for both programs. This includes the ability to participate equally in the costs, profits and losses after opt-in, and to co-promote partnered products in the US.
Dr. Fauci says he expects phase 3 vaccine trials to begin at the end of July. Yahoo Finance's Anjalee Khemlani joins the On the Move panel to discuss where vaccine trials stand.
Markets are clearly different now. I did not grow up, nor was I trained for this environment. Nobody else you hear today was either.
Regeneron Pharmaceuticals stock rose close to a buy point Monday as the drugmaker announced it started late-stage tests on a coronavirus treatment along with partner pharma firm Sanofi.
As for each quarter, Sanofi prepared this document to assist in the financial modeling of the Group's quarterly results. Sanofi's second-quarter 2020 results will be published on July 29, 2020. Sanofi is dedicated to supporting people through their health challenges.
The United States topped over 130,000 new cases of coronavirus over the 4th of July holiday weekend, with Florida and Texas breaking new daily case records. Yahoo Finance’s Anjalee Khemlani breaks down the latest news about the coronavirus on The Final Round.
The coronavirus continued its relentless march across the globe on Monday, with the U.S. recording its worst daily totals to date over the long holiday weekend, with domestic deaths closing in on nearly 130,000.
Dow futures jumped as China markets soar and Covid-19 deaths remain low, with the Nasdaq composite at a record high. What's next for Tesla?
Shares of Regeneron Pharmaceuticals Inc. gained 4.6% in premarket trading on Monday after the drugmaker said it had begun a Phase 3 clinical trial testing an antibody cocktail to prevent COVID-19. The study will specifically focus on the cocktail's efficacy preventing disease in 2,000 people who have been exposed to the virus by a close contact, such as a roommate. The trial is being operated by the National Institute of Allergy and Infectious Diseases. (A separate Phase 2/3 trial for the same antibody cocktail is testing the experimental therapy as a treatment in 2,900 COVID-19 patients who are being treated in hospitals and ambulatory settings. That trial is being run in the U.S. and in other countries like Brazil and Mexico.) On Thursday, Regeneron and Sanofi had announced that a study evaluating their rheumatoid arthritis treatment Kevzara had failed to meet a Phase 3 trial's primary or secondary endpoints in a study testing the drug as a COVID-19 treatment; that announcement sent down Regeneron's shares in after-hours trading. Regeneron's stock is up 65.7% year-to-date, while the S&P 500 is down 3.1%.
Britain is close to a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for 60 million doses of a potential COVID-19 vaccine, the Sunday Times reported. Clinical trials are due to start in September and Sanofi has said it expects to get approval by the first half of next year, sooner than previously anticipated. More than 100 vaccines are being developed and tested around the world to stop the COVID-19 pandemic and governments are racing to secure supplies of vaccines even before their efficacy is proven.
Sanofi (SNY) and Regeneron discontinue U.S.-based phase III coronavirus study on Kevzara following failure to achieve improvement in hospitalized patients with severe COVID-19 patients of statistical significance.
Pfizer (PFE) releases promising early results from its COVID-19 vaccine study. Several new drug/line extensions get approval in the United States, EU and Japan.
Previous trial results had shown that the drug did not help patients with less severe COVID-19, the disease caused by the novel coronavirus, and shares of Regeneron fell about 3% in after hours trading. Other drugs in the same class, including Roche Holding AG's Actemra, are also being studied as treatments for COVID-19. Patients who required mechanical ventilation or high-flow oxygen therapy or treatment in an intensive care unit were considered critically ill.
Shares of Regeneron Pharmaceuticals Inc. were down 2.4% and Sanofi's stock declined 1.7% in after-hours trading on Friday after the companies halted a Phase 3 clinical trial testing their rheumatoid arthritis drug Kevzara as a COVID-19 treatment. The drug, which was being tested in 194 hospitalized COVID-19 patients receiving mechanical ventilation, did not meet the primary or key secondary endpoints in the study. The findings will be published in a peer-reviewed medical journal later this year. Sanofi is continuing to evaluate Kevzara using a different dose in a trial of COVID-19 patients taking place outside of the U.S. Since the start of the year, Regeneron's stock is up 65.7%, shares of Sanofi are up 2.6%, and the S&P 500 is down 3.5%.
July 2, 2020 – Sanofi and Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints when Kevzara was added to best supportive care compared to best supportive care alone (placebo). Minor positive trends were observed in the primary pre-specified analysis group (critical patients on Kevzara 400 mg who were mechanically ventilated at baseline) that did not reach statistical significance and these were countered by negative trends in a subgroup of critical patients who were not mechanically ventilated at baseline1.
The Food and Drug Administration’s new guidance document for developers of Covid-19 vaccines doesn’t spell out a timeline. SVB Leerink analyst Geoffrey Porges says the guidelines point firmly toward no vaccine being made available until next year.
Treatments for peanut allergy and Parkinson's disease are among U.S. drug launches that have been postponed by the COVID-19 pandemic as drugmakers struggle with disruptions to business, a Reuters review of filings and interviews with executives show. The Food and Drug Administration (FDA) has approved more than 30 new medicines since January, but at least five drugmakers including Bristol Myers Squibb, Sanofi , Neurocrine Biosciences, Endo Pharmaceuticals and Aimmune have changed their launch plans.
Spain's Pharma Mar is looking at listing on New York's Nasdaq market, joining a flurry of biotech companies aiming to tap investors' voracious appetite for the sector as it tests one of its therapies to treat COVID-19. The move comes several weeks after the company started mid-stage human trials of cancer drug Aplidin in COVID-19 patients.
Inovio Pharmaceuticals Inc. has yet to share results from the Phase 1 trial for its COVID-19 vaccine candidate, but has already received millions of dollars in funding to scale up manufacturing capacity.
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
French drugmaker Sanofi <SASY.PA>, which employs more than 100,000 people worldwide, confirmed on Friday it will axe up to 1,680 jobs in Europe to cut costs and lift profits. The lay-offs are part of a broader strategy outlined in December by Sanofi CEO Paul Hudson, which includes a cost savings target of 2 billion euros ($2.2 billion) by 2022. A Sanofi spokeswoman said the cuts, mainly affecting blue-collar workers, would be carried out over three years.
Sanofi <SASY.PA> is considering cutting hundreds of jobs and will discuss potential steps with staff representatives over the coming days, five sources said on Thursday, the latest move by the French drugmaker's chief executive Paul Hudson to cut costs. Management will meet staff representatives on Friday and Monday next week to outline a restructuring plan, five sources familiar with the matter told Reuters. The reorganisation could involve several European countries and possibly others outside the region, as well as all the divisions of Sanofi except the vaccines and rare diseases unit Genzyme, the sources said.